NanoGroup S.A.
Warsaw Stock Exchange NNG.WA
NanoGroup S.A. EBITDA for the year ending December 31, 2023: USD -2.00 M
NanoGroup S.A. EBITDA is USD -2.00 M for the year ending December 31, 2023, a -1,114.58% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
-
NanoGroup S.A. EBITDA for the year ending December 31, 2022 was USD -164.32 K, a 93.75% change year over year.
-
NanoGroup S.A. EBITDA for the year ending December 31, 2021 was USD -2.63 M, a -94.18% change year over year.
-
NanoGroup S.A. EBITDA for the year ending December 31, 2020 was USD -1.35 M, a -304.71% change year over year.
-
NanoGroup S.A. EBITDA for the year ending December 31, 2019 was USD -334.46 K, a 52.58% change year over year.
Key data
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
Market news
Loading...
Warsaw Stock Exchange: NNG.WA
| CEO | Mr. Przemyslaw Daniel Mazurek |
| IPO Date | March 14, 2018 |
| Location | Poland |
| Headquarters | Rakowiecka 36 |
| Employees | 46 |
| Sector | Health Care |
| Industries | |
Description
NanoGroup S.A. operates as a biotechnology company. It develops and licenses early-stage biotechnology and medical projects in the areas of oncology, transplantology, and blood donations to international biotech companies and pharmaceutical companies. NanoGroup S.A was incorporated in 2016 and is based in Warsaw, Poland.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email